MedCity News May 9, 2025
Recent FDA guidance aims to improve research inclusivity and the generalizability of clinical findings by ensuring diverse participant representation — it’s about better science, improved patient outcomes, and equitable healthcare access.
Representative clinical studies are important as diseases and medicines can affect people differently depending on their age, sex, and race and ethnicity. According to the Food and Drug Administration (FDA), diversity in clinical trials is not just a regulatory requirement; it is essential for producing reliable data that reflects the varied demographics of the population that will ultimately use these products. Clinical studies that include diverse participants are more likely to yield results that are applicable to the entire patient population.
Recent FDA guidance aims to improve research...
Today's Sponsors
Today's Sponsor